In plain English
CRISPR Therapeutics AG develops gene‑editing medicines using CRISPR technology, targeting rare diseases and cancer. The company trades on…
Company stock · NASDAQ · USD
CRSP
CRISPR Therapeutics AG
—
Price unavailable — company details still show below
- Sector
- Healthcare
- Industry
- Biotechnology
- Size
- Medium-sized company
- Market value
- $4.8 billion
- Number of shares
- 96.7 million
- Country
- CH
- Went public
- Oct 19, 2016
- Exchange
- NASDAQ
- Website
- crisprtx.com
Themes
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What CRSP is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
3 recent cards — open any for the full deeper dive.
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
In brief
Sector rally on mRNA cancer therapy news lifts biotech names, but RXRX’s insider share sale tempers its upside.
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
In brief
Positive Phase 3 cancer trial data for intismeran led to a sharp intraday rally in mRNA stocks, but after‑hours trading saw a pullback as investors took profits or reassessed upside.
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
In brief
Positive earnings and trial results from Estee Lauder, Moderna, and Merck are driving a sharp rally in key large‑cap stocks, boosting confidence in consumer‑discretionary and biotech sectors.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for CRSP will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.